These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 16322324)
1. Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility. Brandt B; Kemming D; Packeisen J; Simon R; Helms M; Feldmann U; Matuschek A; Kersting C; Hinrichs B; Bidart JM; Bellet D; Bartkowiak K; Dankbar N; Dittmar T; Sauter G; Boecker W; Buerger H Endocr Relat Cancer; 2005 Dec; 12(4):823-37. PubMed ID: 16322324 [TBL] [Abstract][Full Text] [Related]
2. [Expression of early placenta insulin-like growth factor (EPIL) in breast cancer cells provides an autocrine loop with enhancement of predominantly HER-2-related invasivity]. Bürger H; Kemming D; Helms M; Feldmann U; Matuschek A; Böcker W; Brandt B Verh Dtsch Ges Pathol; 2005; 89():201-6. PubMed ID: 18035692 [TBL] [Abstract][Full Text] [Related]
3. Early placenta insulin-like growth factor (pro-EPIL) is overexpressed and secreted by c-erbB-2-positive cells with high invasion potential. Brandt B; Roetger A; Bidart JM; Packeisen J; Schier K; Mikesch JH; Kemming D; Boecker W; Yu D; Buerger H Cancer Res; 2002 Feb; 62(4):1020-4. PubMed ID: 11861376 [TBL] [Abstract][Full Text] [Related]
4. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Vazquez-Martin A; Colomer R; Menendez JA Eur J Cancer; 2007 May; 43(7):1117-24. PubMed ID: 17379503 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528 [TBL] [Abstract][Full Text] [Related]
6. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells. Wang K; Ma Q; Ren Y; He J; Zhang Y; Zhang Y; Chen W Oncol Rep; 2007 Jan; 17(1):89-96. PubMed ID: 17143483 [TBL] [Abstract][Full Text] [Related]
7. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer. Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269 [TBL] [Abstract][Full Text] [Related]
8. CdGAP is required for transforming growth factor β- and Neu/ErbB-2-induced breast cancer cell motility and invasion. He Y; Northey JJ; Primeau M; Machado RD; Trembath R; Siegel PM; Lamarche-Vane N Oncogene; 2011 Mar; 30(9):1032-45. PubMed ID: 21042277 [TBL] [Abstract][Full Text] [Related]
9. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Niu G; Carter WB Cancer Res; 2007 Feb; 67(4):1487-93. PubMed ID: 17308086 [TBL] [Abstract][Full Text] [Related]
10. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression. Park SS; Kim SW Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359 [TBL] [Abstract][Full Text] [Related]
11. The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget's disease of the vulva and breast. Ellis PE; Wong Te Fong LF; Rolfe KJ; Crow JC; Reid WM; Davidson T; MacLean AB; Perret CW Anticancer Res; 2002; 22(2A):857-61. PubMed ID: 12014662 [TBL] [Abstract][Full Text] [Related]
12. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647 [TBL] [Abstract][Full Text] [Related]
13. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712 [TBL] [Abstract][Full Text] [Related]
14. Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein. Ogawa T; Nagashima Y; Wada H; Akimoto K; Chiba Y; Nagatani T; Inayama Y; Yao M; Aoki I; Ikezawa Z Hum Pathol; 2005 Dec; 36(12):1273-80. PubMed ID: 16311120 [TBL] [Abstract][Full Text] [Related]
15. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090 [TBL] [Abstract][Full Text] [Related]
16. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway. Yoo YA; Kang MH; Kim JS; Oh SC Carcinogenesis; 2008 Mar; 29(3):480-90. PubMed ID: 18174246 [TBL] [Abstract][Full Text] [Related]
17. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Zhang J; Ren H; Yuan P; Lang W; Zhang L; Mao L Cancer Res; 2006 Jan; 66(1):18-23. PubMed ID: 16397209 [TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346 [TBL] [Abstract][Full Text] [Related]
19. [Geldanamycin inhibits proliferation and motility of human HER2/neu-overexpressing breast cancer cell line SKBr3]. Wang K; Ma QY; Ren Y; He JJ; Chen WK Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1480-4. PubMed ID: 17959518 [TBL] [Abstract][Full Text] [Related]
20. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]